Back to Search Start Over

Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018.

Authors :
Meester, Reinier G. S.
Doubeni, Chyke A.
Zauber, Ann G.
Goede, S. Luuk
Levin, Theodore R.
Corley, Douglas A.
Jemal, Ahmedin
Lansdorp‐Vogelaar, Iris
Source :
Cancer (0008543X); Jul2015, Vol. 121 Issue 13, p2281-2285, 5p
Publication Year :
2015

Abstract

<bold>Background: </bold>The National Colorectal Cancer Roundtable, a national coalition of public, private, and voluntary organizations, has recently announced an initiative to increase colorectal cancer (CRC) screening rates in the United States to 80% by 2018. The authors evaluated the potential public health benefits of achieving this goal.<bold>Methods: </bold>The authors simulated the 1980 through 2030 United States population of individuals aged 50 to 100 years using microsimulation modeling. Test-specific historical screening rates were based on National Health Interview Survey data for 1987 through 2013. The effects of increasing screening rates from approximately 58% in 2013 to 80% in 2018 were compared to a scenario in which the screening rate remained approximately constant. The outcomes were cancer incidence and mortality rates and numbers of CRC cases and deaths during short-term follow-up (2013-2020) and extended follow-up (2013-2030).<bold>Results: </bold>Increasing CRC screening rates to 80% by 2018 would reduce CRC incidence rates by 17% and mortality rates by 19% during short-term follow-up and by 22% and 33%, respectively, during extended follow-up. These reductions would amount to a total of 277,000 averted new cancers and 203,000 averted CRC deaths from 2013 through 2030.<bold>Conclusions: </bold>Achieving the goal of increasing the uptake of CRC screening in the United States to 80% by 2018 may have a considerable public health impact by averting approximately 280,000 new cancer cases and 200,000 cancer deaths within <20 years. Cancer 2015;121:2281-2285. © 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
0008543X
Volume :
121
Issue :
13
Database :
Complementary Index
Journal :
Cancer (0008543X)
Publication Type :
Academic Journal
Accession number :
103287117
Full Text :
https://doi.org/10.1002/cncr.29336